Patents by Inventor Ewen F. Kirkness
Ewen F. Kirkness has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080317754Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: ApplicationFiled: June 1, 2007Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 7365163Abstract: The present invention relates to a novel GABAA receptor ? subunit (GABRE) and an alternative transcript thereof (ET2). More specifically, isolated nucleic acid molecules are provided encoding human GABRE and ET2 receptor subunits. ET2 and GABRE polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of ET2 and GABRE activities. Also provided are diagnostic methods for detecting aberrant GABRE and ET2 expression, as well as therapeutic methods for treating disorders involving ET2 and GABRE.Type: GrantFiled: February 3, 2006Date of Patent: April 29, 2008Assignee: Human Genome Sciences, Inc.Inventors: Michael C. Hanna, Ewen F. Kirkness
-
Patent number: 7235371Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: July 21, 2005Date of Patent: June 26, 2007Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 7029870Abstract: The present invention relates to a novel GABAA receptor ? subunit (GABRE) and an alternative transcript thereof (ET2). More specifically, isolated nucleic acid molecules are provided encoding human GABRE and ET2 receptor subunits. ET2 and GABRE polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of ET2 and GABRE activities. Also provided are diagnostic methods for detecting aberrant GABRE and ET2 expression, as well as therapeutic methods for treating disorders involving ET2 and GABRE.Type: GrantFiled: February 26, 1998Date of Patent: April 18, 2006Assignee: Human Genome Sciences, Inc.Inventors: Michael C. Hanna, Ewen F. Kirkness
-
Patent number: 6994978Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: December 4, 2003Date of Patent: February 7, 2006Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Publication number: 20040248245Abstract: Novel zinc activated ion channel (ZAC) polypeptides, proteins and nucleic acid molecules are provided. In addition to isolated, full-length ZAC proteins, isolated ZAC fusion proteins, antigenic peptides and anti-ZAC antibodies are provided. Moreover, ZAC nucleic acid molecules, recombinant expression vectors containing a nucleic acid encoding ZAC, host cells into which the expression vectors have been introduced and nonhuman transgenic animals in which a ZAC gene has been introduced or disrupted are provided. Diagnostic, screening and therapeutic methods utilizing ZAC compositions or composition that detect, bind or modulate ZAC also are provided. Methods for identifying ZAC agonists, antagonists, inverse agonists and the like are described.Type: ApplicationFiled: June 9, 2003Publication date: December 9, 2004Inventors: Ewen F. Kirkness, Tim G. Hales, Paul A. Davies
-
Patent number: 6790826Abstract: Disclosed are human haemopoietic maturation factor polypeptides and DNA (RNA) encoding such haemopoietic maturation factor polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and for using such polypeptides for treating leukemia, auto-immune diseases and blood related disorders. Antagonists against such polypeptides and their use as a therapeutic to prevent expansion of T-cell populations are also disclosed. Diagnostic assays are also disclosed to detect both the presence of mutations in the haemopoietic maturation factor nucleic acid sequences and altered levels of the protein.Type: GrantFiled: December 7, 2001Date of Patent: September 14, 2004Assignee: Human Genome Sciences, Inc.Inventors: Ewen F. Kirkness, Mark D. Adams, Henrik Olsen, Craig A. Rosen
-
Patent number: 6680375Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: April 3, 2002Date of Patent: January 20, 2004Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 6620619Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: GrantFiled: March 16, 1994Date of Patent: September 16, 2003Assignee: Human Genome Sciences, Inc.Inventors: William A. Haseltine, Steven Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Craig A. Rosen, Rebecca A. Fuldner, Ewen F. Kirkness
-
Patent number: 6610477Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a procedure for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.Type: GrantFiled: June 6, 1995Date of Patent: August 26, 2003Assignees: Human Genome Sciences, Inc., The Johns Hopkins UniversityInventors: William A. Haseltine, Steven M. Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, Craig A. Rosen, Bert Vogelstein, Kenneth W. Kinzler, Nicholas C. Nicolaides, Nickolas Papadopoulos
-
Publication number: 20030087226Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: ApplicationFiled: March 16, 1994Publication date: May 8, 2003Inventors: WILLIAM A. HASELTINE, STEVEN RUBEN, YING-FEI WEI, MARK D. ADAMS, ROBERT D. FLEISCHMANN, CLAIRE M. FRASER, CRAIG A. ROSEN, REBECCA A. FULDNER, EWEN F. KIRKNESS
-
Patent number: 6552174Abstract: A human hMutT2 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for hydrolyzing and eliminating oxidized guanine nucleotides from the nucleotide pool to ensure correct DNA synthesis. Diagnostic assays are also disclosed which detect the presence of a mutated form of hMutT2 and over-expression of the hMutT2 protein.Type: GrantFiled: October 12, 2001Date of Patent: April 22, 2003Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Ewen F. Kirkness
-
Publication number: 20030027177Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a prodeudre for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.Type: ApplicationFiled: February 22, 2002Publication date: February 6, 2003Applicant: Human Genome Sciences, Inc.Inventors: William A. Haseltine, Steven M. Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, Craig A. Rosen
-
Patent number: 6482606Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: GrantFiled: January 27, 1994Date of Patent: November 19, 2002Assignee: Human Genome Sciences, Inc.Inventors: Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, William A. Haseltine, Craig A. Rosen, Steve Ruben, Ying-Fei Wei
-
Patent number: 6475766Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: November 7, 1995Date of Patent: November 5, 2002Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 6475487Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases. A patient is treated by administering an antibody produced against a polypeptide consisting of SEQ ID NO: 2.Type: GrantFiled: September 18, 2001Date of Patent: November 5, 2002Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H Drake, Maxine Gowan
-
Publication number: 20020146408Abstract: Disclosed are human haemopoietic maturation factor polypeptides and DNA (RNA) encoding such haemopoietic maturation factor polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and for using such polypeptides for treating leukemia, auto-immune diseases and blood related disorders. Antagonists against such polypeptides and their use as a therapeutic to prevent expansion of T-cell populations are also disclosed. Diagnostic assays are also disclosed to detect both the presence of mutations in the haemopoietic maturation factor nucleic acid sequences and altered levels of the protein.Type: ApplicationFiled: December 7, 2001Publication date: October 10, 2002Applicant: Human Genome Sciences, Inc.Inventors: Ewen F. Kirkness, Mark D. Adams, Henrik S. Olsen, Craig A. Rosen
-
Patent number: 6462188Abstract: Recombinant materials for preparation of a new form of human 5-HT3 receptor are provided. These materials permit the production of said receptor, display of said receptor on host cells, and compositions of diagnostic and therapeutic utility.Type: GrantFiled: April 16, 1998Date of Patent: October 8, 2002Assignee: The Institute for Genomic ResearchInventor: Ewen F. Kirkness
-
Publication number: 20020142448Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: ApplicationFiled: April 3, 2002Publication date: October 3, 2002Applicant: Human Genome Sciences, Inc.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Publication number: 20020102588Abstract: A human hMutT2 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for hydrolyzing and eliminating oxidized guanine nucleotides from the nucleotide pool to ensure correct DNA synthesis. Diagnostic assays are also disclosed which detect the presence of a mutated form of hMutT2 and over-expression of the hMutT2 protein.Type: ApplicationFiled: October 12, 2001Publication date: August 1, 2002Applicant: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Ewen F. Kirkness